Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China
From the perspective of U.S. payers, Erdafitinib as a second-line treatment for mUC is not cost-effective. From the perspective of China, the cost-effectiveness of Erdafitinib is highly sensitive to its price, which could provide a reference for healthcare reimbursement negotiations.
Authors
- Ouyang Xie
- Heng Xiang
- Andong Li (ORCID: https://orcid.org/0000-0001-5291-2720)
- Kehui Meng
- Meiyu Wu
- Xiaomin Wan
Institutions
- Central South University (CN)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-05-10
- DOI
- https://doi.org/10.1080/14796694.2025.2504321
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province